The application of network mapping in differential diagnosis of parkinsonian disorders
暂无分享,去创建一个
[1] D. Margouleff,et al. Positron emission tomographic findings in Filipino X‐linked dystonia–parkinsonism , 1993, Annals of neurology.
[2] Angelo Antonini,et al. Tc‐99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism , 2002, Movement disorders : official journal of the Movement Disorder Society.
[3] Mircea Ariel Schoenfeld,et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging , 2004, NeuroImage.
[4] W. Martin,et al. The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[5] J R Moeller,et al. The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[6] David Eidelberg,et al. The metabolic pathology of dopa‐responsive dystonia , 2005, Annals of neurology.
[7] Willibald Gerschlager,et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study , 2002, Movement disorders : official journal of the Movement Disorder Society.
[8] A. Rajput,et al. Prevalence of movement disorders in elderly community residents. , 1994, Neuroepidemiology.
[9] A. Parent,et al. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidium in basal ganglia circuitry , 1995, Brain Research Reviews.
[10] V. Dhawan,et al. SPECT imaging in Parkinson's disease. , 2001, Advances in neurology.
[11] J R Moeller,et al. The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies , 1990, Movement disorders : official journal of the Movement Disorder Society.
[12] Alan C. Evans,et al. Dopa decarboxylase activity of the living human brain. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[13] S. Gilman,et al. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] Anthony E. Lang,et al. Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics , 2005 .
[15] I Litvan,et al. Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1994, Neurology.
[16] David Eidelberg,et al. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] D. Eidelberg,et al. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] James Ralph Moeller,et al. Highly automated computer-aided diagnosis of neurological disorders using functional brain imaging , 2006, SPIE Medical Imaging.
[19] V. Dhawan,et al. Abnormal Metabolic Network Activity in Parkinson'S Disease: Test—Retest Reproducibility , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[20] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[21] K. Leenders,et al. Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride , 1997, Movement disorders : official journal of the Movement Disorder Society.
[22] B. Giraudeau,et al. Quantitative analysis of striatal dopamine D2 receptors with 123I-iodolisuride SPECT in degenerative extrapyramidal diseases , 2001, Nuclear medicine communications.
[23] Nir Giladi,et al. Metabolic topography of the hemiparkinsonism‐hemiatrophy syndrome , 1994, Neurology.
[24] Anna Barnes,et al. FDG PET in the differential diagnosis of parkinsonian disorders , 2005, NeuroImage.
[25] T. Ishikawa,et al. Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] Jan Booij,et al. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism , 2001, European Journal of Nuclear Medicine.
[27] David Eidelberg,et al. Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging , 2007, Movement disorders : official journal of the Movement Disorder Society.
[28] T. Ishikawa,et al. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] V. Dhawan,et al. 10 – Movement Disorders: Parkinson's Disease , 2000 .
[30] J R Moeller,et al. Early differential diagnosis of Parkinson's disease with 18F‐fluorodeoxyglucose and positron emission tomography , 1995, Neurology.
[31] M. Ghilardi,et al. Effects of levodopa infusion on motor activation responses in Parkinson’s disease , 2002, Neurology.
[32] V. Dhawan,et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease , 2001, Annals of neurology.
[33] Robert B. Innis,et al. [123I]β‐CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy , 2001 .
[34] N. Quinn,et al. Multiple system atrophy: A review of 203 pathologically proven cases , 1997, Movement disorders : official journal of the Movement Disorder Society.
[35] David Eidelberg,et al. The role of functional neuroimaging in the differential diagnosis of idiopathic Parkinson’s disease and multiple system atrophy , 2004, Clinical Autonomic Research.
[36] A. Parent,et al. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop , 1995, Brain Research Reviews.
[37] Jean-Claude Baron,et al. Executive processes in Parkinson's disease: FDG‐PET and network analysis , 2004, Human brain mapping.
[38] Yaakov Stern,et al. Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance , 2004, NeuroImage.
[39] V. Dhawan,et al. 75 – PET Imaging in Parkinson's Disease and Other Neurodegenerative Disorders , 2007 .
[40] J. C. Stoof,et al. [123I]β-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls , 1997, European Journal of Nuclear Medicine.
[41] T. Ishikawa,et al. The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[42] C D Marsden,et al. Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.
[43] Klaus Seppi,et al. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. , 2005, Brain : a journal of neurology.
[44] Daniel Tarsy,et al. Adverse effects of subthalamic nucleus DBS in a patient with multiple system atrophy , 2003, Neurology.
[45] V. Dhawan,et al. Network modulation in the treatment of Parkinson's disease. , 2006, Brain : a journal of neurology.
[46] A. Eisen,et al. Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam. , 1990, Archives of neurology.
[47] Luc Mortelmans,et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[48] J. Seibyl,et al. [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression , 2001, Neurology.
[49] C Kremser,et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy , 2003, Neurology.
[50] J R Moeller,et al. Divergent expression of regional metabolic topographies in Parkinson's disease and normal ageing. , 1997, Brain : a journal of neurology.
[51] M. Delong,et al. Functional and pathophysiological models of the basal ganglia , 1996, Current Opinion in Neurobiology.
[52] V. Dhawan,et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[53] V Kaasinen,et al. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[54] David Eidelberg,et al. Modulation of regional brain function by deep brain stimulation: studies with positron emission tomography , 2002, Current opinion in neurology.
[55] V. Dhawan,et al. Radiosynthesis of [18F] N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl) nortropane and the first human study with positron emission tomography , 1996 .
[56] Yoav Ben-Shlomo,et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.
[57] U. Haberkorn. PET and SPECT. , 2008, Handbook of experimental pharmacology.
[58] V. Dhawan,et al. Reproducibility of regional metabolic covariance patterns: comparison of four populations. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[59] C. Patlak,et al. Combined FDOPA and 3OMFD PET studies in Parkinson's disease. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[60] Masanori Ichise,et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP , 2002, Movement disorders : official journal of the Movement Disorder Society.
[61] Koen Van Laere,et al. Quantification of Parkinson’s disease-related network expression with ECD SPECT , 2007, European Journal of Nuclear Medicine and Molecular Imaging.